Intrexon Corp., of Germantown, Md., completed the acquisition of Medistem Inc., of San Diego. The $26 million acquisition provides Intrexon with a platform of endometrial regenerative cells derived from menstrual blood for use with integrated synthetic biology platforms to develop cell-based therapies across a range of conditions.